Although the thrombolytic activity of tissue-type plasminogen activator (t-PA) may be beneficial in the acute treatment of stroke, recent studies have suggested that this ser ine protease could also play a critical role in determining the extent of neuronal death after injury to the central nervous system (CNS). This hypothesis is based on several experimen tal results: t-PA-deficient mice are resistant to excitotoxic neu ronal death induced by the intrahippocampal injection of kain ate; the infarct volume induced by occlusion of the middle cerebral artery is reduced in t-PA knockout mice; and the in travenous injection of t-PA can under certain circumstances potentiate the infarct volume in animals subjected to middle cerebral artery occlusion. In the CNS, the serine proteases have been identified to occur both in neurons and glial cells. Their enzymatic activity regulates the balance between the accumulation and the degra dation of the extracellular matrix. They are involved in many physiologic functions, ranging from synaptic outgrowth during perinatal development to plasticity in adults. For instance, thrombin and t-PA are known to modulate neurite outgrowth
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In the CNS, the serine proteases have been identified to occur both in neurons and glial cells. Their enzymatic activity regulates the balance between the accumulation and the degra dation of the extracellular matrix. They are involved in many physiologic functions, ranging from synaptic outgrowth during perinatal development to plasticity in adults. For instance, thrombin and t-PA are known to modulate neurite outgrowth Because the usual causes of stroke are related to thromboembolic processes in cerebral arteries, the idea that the prevention of clot formation might be helpful for patients was understood as early as the 1940s. After un successful clinical trials using different pharmacologic agents (e.g., streptokinase or urokinase) directed toward the pathway for lysis of clots, the National Institutes of Health recommended in the 1980s the use of tissue-type plasminogen activator (t-PA) for the treatment of throm boembolic diseases. In 199 1, an advanced study was and tissue remodeling in the early stages of development. In the adult brain, t-PA may contribute to the late phase of long-term potentiation and to the subsequent synaptic growth in the hip pocampal mossy fiber pathway.
This balance between the degradation and accumulation of the extracellular matrix may also be integral to various patho logic processes involved in acute brain injury. For example, compounds that modulate the activity of serine proteases ex hibit neuroprotective activity. Based on the above, numerous studies have focused on the production and modulation of the endogenously produced serine protease inhibitors, termed ser pins, such as type 1 plasminogen activator inhibitor, neuroser pin, and protease nexin-1.
In the present review, we will discuss the need to distinguish between the potentially neurotoxic effects of t-PA and its ben eficial effect on reperfusion. We will present data supporting the idea that the modulation of serine protease activity may represent a novel and efficient strategy for the treatment of acute cerebral injury in humans. Key Words: t-PA Ischemia-Cerebral-Therapeutic. initiated to study the effects of t-PA (Hacke et aL, 1995) . Although the clinical results were not conclusive, the authors suggested that recombinant t-PA (rt-PA) treat ment (at 1. 1 mg/kg) after the onset of stroke speeded neurologic recovery. In 1995 (Adams et aI., 1995) , the National Institute of Neurological Disorders rt-PA Stroke Study Group conducted a randomized, double blind, placebo-controlled study of the effect of the intra venous injection of t-PA within 3 hours after the onset of symptoms in 624 patients. This time, the results of the clinical study were more conclusive: t-PA administration produced an absolute increase of 11 % to 13% in the proportion of patients who regained normal neurologic function without increasing the fraction that had a poor outcome. Although t-PA treatment induced a 10-fold in crease in the rate of symptomatic intracerebral hemor rhage, ischemic brain damage was reduced. Notwith standing these secondary effects, the intravenous injec tion of t-PA was approved by the Food and Drug Administration as the first agent acknowledged for the treatment of focal cerebral infarction. The same year, a report that described the participation of t-PA in excito toxic neuronal death was published (Tsirka et a!., 1995) . Since then, numerous studies have been conducted to determine the role of serine proteases and their natural inhibitors (serpins) in physiologic and pathologic condi tions.
In this brief review we will first discuss the expression pattern of serine proteases and their inhibitors in the healthy and injured brain. Then we will present experi mental data to demonstrate the involvement of serine proteases in various types of neuronal injury. Finally, we will advance the hypothesis that although the thromboly sis induced by t-PA may exert a beneficial activity in the treatment of acute stroke, t-PA may play other roles as well, some of which might be deleterious to brain tissue. Based on the literature reviewed, we suggest that the modulation of the activity of serine proteases may rep resent a novel therapeutic target for limiting the extent of acute and neurodegenerative brain damage.
EXPRESSION OF SERINE PROTEASES AND THEIR COGNATE INHIBITORS
The serine proteases are a superfamily of proteins in which most members exert their proteolytic activity by cleavage after the amino acid arginine (Table 1) . These proteins have been studied extensively in relation to co agulation and thrombolysis (Carmeliet and Collen, 1997) . In addition to their existence in the blood com partment, several of these proteases have been localized in the central nervous system (CNS). The CNS serine proteases most studied are the plasminogen acti vators (t-PA and urokinase-type plasminogen activator [u-PA)) and thrombin, which are thought to play a critical role in CNS homeostasis. Mulligan et al. (1991) t-PA, tissue-type plasminogen activator; u-PA, urokinase-type plas minogen activator; PAl-I, type I inhibitor of plasminogen activator; PN-I, protease nexin-l. The maintenance of vascular patency and the dissolu tion of fibrin clots are key functions of plasminogen. Plasminogen is a proenzyme that can be converted to the active enzyme, plasmin, by different types of activators. Two physiologic plasminogen activators, t-PA and u-PA, have been identified, initially based on their immuno logic relations with the plasminogen found in urine.
t-PA, the predominant plasminogen activator in blood, is a serine protease with a molecular weight of 60 to 70 kDa and is synthesized and secreted by endothelial cells in a single-chain form. This form is cleaved by the plas min into the double-chain form held together by a disul fite bond (Lijnen et a!., 1980) . In the brain, t-PA is in volved in the catabolism of the extracellular matrix through the conversion of the inactive plasminogen to the protease plasmin ( Fig. 1) . Although there is no clear evidence of an obligatory interaction between t-PA and a membrane-bound receptor to initiate proteolysis, t-PA can interact with the cell surface by means of the cal cium-regulated phospholipid-binding protein annexin II (Hajjar et a!., 1998) . The expression of annexin II has been detected in the developing murine CNS (Hamre et a!., 1995) , but its distribution in the adult brain remains to be established. During embryogenesis, increased t-PA expression coincides with extensive cell migration, pro liferation, and tissue remodeling in the CNS (Friedman and Seeds, 1995) . The first report of the implication of t-PA in cell migration was obtained from differentiated lines of neuroblastoma cells. A fibrin overlay assay re vealed that the predominant site of t -P A activity was on the growth cones (Krystosek and Seeds, 198 1) . Cerebral t-PA mRNA levels are modulated according to the stage of development. Northern blot analyses performed on mouse brain revealed that t-PA mRNA levels are low from embryonic day 1 to day 7, increase from postnatal day 1 to day 7, and thereafter decline about threefold in the adult (Friedman and Seeds, 1994) . In the mature brain, t-PA is synthesized by neurons in most regions, with the most prominent expression in the hippocampus and hypothalamus (Sappino et aI., 1993) . In vitro, t-PA mRNAs are detected in both cultured cortical neurons and astrocytes (Buisson et ai., 1998) . The earliest data on the physiologic role of t-PA were obtained from mice in which the t-PA gene was rendered nonfunctional (t-PA -/-) (Carmeliet et aI., 1994) . These knockout mice dis played a selective reduction in the late phase of the phe nomenon of long-term potentiation (Huang et aI., 1996) . Similarly, the administration of inhibitors of t-PA pro teolytic activity such as endogenous plasminogen activa tor inhibitor, type 1 plasminogen activator inhibitor (PAl-I), or a synthetic t-PA inhibitor, t-PA stop, inhibit the long-term potentiation induced in the mossy fibers of the hippocampus (Baranes et ai., 1998) . In summary, the available evidence indicates that t-PA is central to the regulation of neuroplasticity in both in the developing and mature brain.
u-PA, a second serine protease involved in the activa tion of plasminogen, has a molecular weight of 54 kDa. To be activated, u-PA requires conversion by plasmin from an inactive single chain to a catalytically active double-chain derivative (Lijnen et ai., 1980) . The major difference between t-PA and u-PA is that u-PA needs to be bound to a specific cell surface receptor, the urokinase plasminogen activator receptor. This feature gives u-PA a precise localization for its proteolytic activity that af fects the degradation of the extracellular matrix (Yama moto et aI., 1994). During embryonic development, u-PA is expressed throughout the growth process of neurons and astrocytes in the cerebellum, hippocampus, and ce rebral cortex. These data suggest that the function of u-PA is related to cell proliferation, migration, and dif ferentiation during brain development (Tranque et ai., 1992 (Tranque et ai., , 1994 . In the adult, in situ hybridization in mice has shown that u-PA is predominantly expressed in the subiculum, the entorhinal and parietal cortices, and in the hippocampus (Mas os and Miskin, 1996) . The physi ologic role of u-PA in the CNS should be further inves tigated.
The serine protease thrombin (38 kDa) is a key com ponent in the coagulation cascade and is also localized in the CNS. Thrombin exerts its effects via a G-protein coupled protease-activated receptor (PAR-I) that is found on the cell surface. These receptors are cleaved by thrombin and then undergo a conformational change that leads to their activation. Both neuronal and glial cells express the thrombin precursor prothrombin and the PAR-I transcript (Niclou et ai., 1994) . In situ hybridiza tion experiments have revealed a ubiquitous but low intensity signal for PAR-I mRNA in the late embryonic and early postnatal nervous systems. In the adult, PAR-l expression is more pronounced but is confined to specifi c neurons such as mesencephalic dopaminergic and cerebellar Purkinje cells (Niclou et aI., 1998) . In summary, the role of thrombin in the CNS seems distinct from its function in the coagulation system, but its physi ologic importance remains to be established.
A novel and brain-specific serine protease, neuropsin (55 kDa), has been recently identified (Chen et ai., 1995; Scarisbrick et aI., 1997) . This protease is markedly ex pressed in the neurons of the murine limbic system and in the pyramidal neurons of the hippocampus. This re stricted localization could imply involvement in neural plasticity (Tomizawa et ai., 1999) .
In biologic systems, the activity of serine proteases depends on their equilibrium with their serine protease inhibitors, termed serpins. These serpins act as a pseu dosubstrate for their target protease(s) and establish a tight bond with the catalytic site. By attenuating extra cellular proteolysis, serpins modify the processes that involve the proteolysis of the extracellular matrix such as neuronal migration, axogenesis, or the formation of ma ture synaptic connections. Two major inhibitors of t-PA have been identified in the brain: PAI-I (50 kDa) (see Fig. I ) and the neuroserpin (55 kDa). PAI-l is a fast acting inhibitor of t-PA and u-PA and has been shown to be present in the rodent cerebral cortex. In vitro studies have revealed that the PAI-l mRNA and the protein are exclusively restricted to astrocytes. PAI-l mRNA and protein are not detected in cultured cortical neurons (Docagne et ai., 1999) .
Initially identified as an axonally secreted protein in cultured chicken neurons taken from the dorsal root gan glion, neuroserpin is a serine protease inhibitor present both in the developing and in the adult murine nervous system (Berger et ai., 1998; Hastings et aI., 1997; Krue ger et aI., 1997) . In the adult CNS, neuroserpin is ex pressed predominantly in the neocortex, the hippocampal formation, the olfactory bulb, and the amygdala (Hast ings et aI., 1997; Krueger et aI., 1997) . In vitro, murine cortical neurons and astrocytes both express neuroserpin mRNA (Docagne et aI., 1999) .
Protease nexin I (PN-I) (44 kDa) is the most potent tissue inhibitor of thrombin known (Smirnova et aI., 1996) . In situ hybridization performed during embryonic CNS development has shown expression of PN-l in the mesencephalon (Kury et aI., 1997) . In the developing postnatal brain, PN-l expression appears transiently in many neuronal populations (Mansuy et ai., 1993) . Fur ther, in vivo studies have shown that the expression of PN-I is abundant not only in the astrocytes of the pa renchyma but also in the perivascular astroglial end feet (Choi et aI., 1990) . In vitro, there is evidence of expres sion of PN-I mRNA in both cortical neurons and astro cytes (Docagne et aI., 1999) . The presence of PN-I has also been detected in Schwann cell cultures (Mulligan et aI., 199 1) . Studies performed in the adult human cerebral cortex have revealed a pronounced immunoreactivity for PN-l in capillaries and in the smooth muscle cells of arteries and arterioles (Choi et a!., 1990) .
INVOLVEMENT OF SERINE PROTEASES AND INHIBITORS DURING NEURODEGENERA TIVE DISEASE
Various studies have shown that the expression of serine proteases is modulated during brain injury (Qian et a!., 1993) . However, their involvement in the consequent neuronal damage remains controversial ( Table 2 ).
In 1995, it was reported for the first time that t -P A mediates neuronal cell death induced by the intrahippo campal injection of kainic acid in mice (Tsirka et a!., 1995) . Explicitly, these authors observed that t-PA deficient mice display a dramatic resistance to the exci totoxic injury induced by this glutamate agonist. To analyze the mechanism by which t-PA-deficient mice were resistant to the neurotoxin, the same group sub jected mice deficient in plasminogen, the zymogen sub strate of t-PA, to the same type of injury. They showed that the intrahippocampal injection of kainic acid in duced a minimal degeneration in the plasminogen deficient mice, whereas fibrin-deficient mice displayed a vulnerability to the excitotoxin similar to that seen with the wild-type animals (Tsirka et a!., 1997a) . These re sults were further strengthened by the observation that the infusion of a2-antiplasmin, the physiologic plasmin inhibitor, into the hippocampus of wild-type mice con fers neuroprotection against excitotoxic damage (Tsirka et aI., 1997b) . Moreover, intrahippocampal delivery of plasminogen to plasminogen-deficient mice restored de generation induced by glutamate analogue injection to wild-type levels, but intravenous delivery did not (Chen et aI., 1999) , These results suggest that excitotoxic neu ronal death and blood-brain barrier breakdown are inde pendent processes. The same group (Chen and Strick land, 1997) clarified the potential role of plasmin in neu ronal excitotoxic mechanisms by identifying a target protein, laminin, cleaved by plasmin in response to a kainate infusion. These authors showed that the intrahip pocampal injection of kainic acid induces a loss of the laminin immunoreactivity that precedes neuronal death. This laminin cleavage and the neuronal death subsequent to the kainate injection were abolished in t-PA-deficient mice or when kainate was coinjected with a2-anti plasmin into the hippocampus of wild-type mice. These results indicate that the cleavage of plasminogen into plasmin by t-PA is a key step in the excitotoxic cascade, Because excitotoxic neuronal injury is thought to par ticipate in ischemia-induced brain damage, it was impor tant to test the implication of a t-PA/plasmin pathway in an animal model of cerebral ischemia, This step was achieved in 1998 by Wang et a!., who demonstrated that t-PA-deficient mice subjected to 3 hours of middle ce rebral artery occlusion (MCAO) exhibited a 50% reduc tion in the infarct volume compared with wild-type mice.
These data have been confirmed by Nagai et a!. (1999) , who showed that the infarct size induced by a permanent MCAO is threefold smaller in t-PA-deficient mice than in wild-type animals. The implication of t-PA in isch emia-induced neuronal cell death was strengthened by the results obtained in PAl-I-deficient mice. When sub jected to permanent MCAO, PAl-I-deficient mice exhib ited a twofold increase in infarct volume. No modifica tion of the infarct size was observed in u-PA-deficient mice (Nagai et a!., 1999) . Taken together, these data suggest that t-PA is involved in the deleterious cascade of events leading to ischemia-induced neuronal death. In these latter studies, the involvement of plasmin in the t-PA deleterious effect during cerebral ischemia remains controversial. In contrast to the previous investigations, in which a lesion was induced by the intrahippocampal injection of an excitotoxin, Nagai et al. (1999) reported that plasminogen-deficient mice subjected to MCAO ex hibited a larger infarct volume compared with wild-type animals. Similarly, mice with an increased plasmin ac tivity (a2-antiplasmin-deficient mice) were resistant to an ischemic insult.
The cellular origin of the t-PA present in brain tissues after CNS injury is not well characterized. It has been suggested that t-PA is produced by activated microglial cells in response to the neuronal injury induced by an intrahippocampal injection of kainic acid (Rogove and Tsirka, ] 998; Tsirka, 1997) . However, experiments per formed with the "neuronal-like" cell line PC-12 demon strate an activity-dependent secretory mechanism that can rapidly increase the amount of t-PA (Gualaudris et aI., 1996) . These authors suggested that t-PA could be stored in vesicles and released along with neurotransmit ters. Thus, during hypoxic depolarization, t-PA could be released with glutamate into the extracellular space and participate in the excitotoxic pathway leading to isch emic neuronal death.
The resistance of t-PA-deficient mice to ischemic in sults raises the question of whether the potentially del eterious effect of rt-PA is independent of its beneficial thrombolytic activity. To test this hypothesis, it was con sidered necessary to use a treatment with rt-PA in an animal model of cerebral ischemia that did not involve the formation of a thrombus. Wang et al. (1998) demon strated that the intravenous injection of rt-PA (I mg/kg) 20 minutes after MCAO with an intravascular filament increased the lesion induced by 120 minutes of MCAO. These data support the idea that the intravenous injection of rt -P A promotes undesirable effects by potentiating the extent of the lesion. However, this result remains con troversial: two other groups have reported cont1icting results. Kilic et al. (1999) showed that the intravenous injection of rt-PA (10 mg/kg) 15 minutes after the onset of a 90-minute transient MCAO in mice reduces the ischemic injury. Klein et al. (1999) showed that the in travenous injection of rt-PA does not exacerbate isch emia-induced lesions in models of global and focal ce rebral injury in rats.
Recently, other workers have suggested that t-PA could also exert a neuroprotective role independent from its catalytic activity. Kim et al. (1999) have described a neuroprotective effect of t-PA against zinc-induced neu ronal death in vitro as well as in a model of free radical mediated neuronal injury in murine cortical cell cultures. They strengthened their preliminary observations by in jecting t-PA into the cerebrospinal fluid (CSF) of ani mals subjected to kainate-induced seizures. This treat ment reduced both zinc translocation into neurons and the subsequent kainate-induced neuronal death in the hippocampus. They postulated that the neuroprotective effect of the t-PA treatment does not involve its proteo lytic activity.
The role of other serine proteases in acute brain injury or neurodegenerative diseases has not been extensively studied. However, thrombin has been shown to exert deleterious effects on both neurons and astrocytes in vitro. These effects, ranging from neurite retraction to induction of apoptotic cell death, appear to be mediated through an interaction with thrombin cell surface recep tors and are prevented by PN-I (Turgeon and Houenou, 1997; Turgeon et aI., 1998) . For example, synthetic pep tides that directly activate the thrombin receptor have been shown to induce apoptosis (Donovan et aI., 1997) . The neurotoxic effects of the (3-amyloid protein on cul tured neurons can be potentiated by the activation of the thrombin receptor (Pike et aI., 1996) . Taken together, these data suggest the participation of thrombin in certain cell death pathways that are involved in neurodegenera tive diseases. However, thrombin has been shown to ex ert a neuroprotective role in various types of injury. It has been reported that thrombin protects rat primary hippo campal neurons from cell death induced by hypoglyce mia or growth supplement deprivation (Vaughan et aI., 1995) and to reduce rat astrocytic death induced by hy poglycemia or oxidative stress (Vaughan et aI., 1995) . Overall, these data underline the potential participation of thrombin in various neurologic disorders.
With respect to the potential involvement of serine proteases in neurodegenerative diseases, an impairment in the balance between serine proteases and their cognate inhibitors in the CNS may lead to a pathologic state. Accordingly, it is important to study the level of expres sion of serpins in various neurodegenerative conditions. In humans, it has been reported that the expression of the most potent inhibitor of t-PA, PAl-I, is increased in the CSF from patients with neurologic disorders such as Alz heimer disease, cerebral infarction, CNS infection, and CNS neoplasia. Overall, there was no correlation be tween plasma and CSF levels of PAI-l. These observa tions suggest that CSF PAI-l levels may represent a nonspecific marker of CNS disease (Sutton et aI., 1994) . Similar results were obtained in experimental models of cerebral ischemia in rodents. After permanent focal ce rebral ischemia in mice, semiquantitative RT-PCR ( Fig.  2A) and in situ hybridization studies revealed that PAI-I is overexpressed 24 hours to 3 days later at the border of the ischemic core and in tissues that matched GF AP immunostaining (Docagne et aI., 1999) . This up regulation of PAl -1 expression has also been observed as early as 6 hours after the onset of focal ischemia in rats (Docagne et aI., unpublished results) .
Other serine protease inhibitors may also be modu lated after brain injury. PN-I expression is up-regulated in glial cells after different types of CNS lesions that are 2. (A) Modulation of the expression of serpins and tissue-type plasminogen activator (t-PA) mRNAs after permanent focal ischemia in murine cortex. Total RNA from lesioned (I, ipsilateral) and contralateral (C) brain cortices were isolated at the times indicated and analyzed by RT-PCR for type 1 plasminogen activator inhibitor (PAI-1), t-PA, neuroserpin (NSP), protease nexin 1 (PN-1), and [3-actin. An individual animal was used at each time. The RT-PCR results presented in this figure are representative of results obtained from three individual experiments. Sham 12 hours: mRNA from sham-operated mice without middle cerebral artery occlusion harvested 12 hours after the surgery. Only PAI-1 was overexpressed after cerebral ischemia at time pOints 24 hours and 3 days. (8) PAI-1 expression induced by transforming growth factor-[3 1 (TGF-[31) selectively protects neurons against N-methyl-D-aspartate (NMDA)-induced necrosis in mixed neuron and glial cultures. Cell death (%) was estimated by LDH release (mean ± standard error of the mean, n = 12) in mixed cultures either under control conditions or after 24 hours' exposure to 12.5 IJmoi/L NMDA without or with 1 ng/mL TGF-[31 in the presence or absence of an antibody raised against PAI-1. NMDA-mediated neuronal cell death was also estimated in the presence of recombinant PAI-1 (recPAI-1, 1 IJg/mL). 'significantly different from NMDA + TGF-[31; 'significantly different from NMDA alone by one-way analysis of variance followed by Student-Newman-Keuls test for multiple comparisons (P < 0.05).
associated with a disruption of the blood-brain barrier (Erno et aI., 1996) . In some cases, this expression per sists 1 year after the induction of transient global isch emia in rat brain (Nitsch et aI., 1993) . In contrast, a marked reduction of PN-I and PN-2/�-amyloid protein precursor is observed in the brain of patients with Alz heimer disease (Choi et aI., 1995) .
Overall, these observations suggest that serpins may influence the outcome of brain injury. Experimental data support this postulate. Tsirka et al. (1997 b) have men tioned that PAl -J confers extensive neuroprotection after a hippocampal excitotoxic lesion. In vitro, PAI-l pro duced by astrocytes is neuroprotective against necrosis mediated by N-methyl-o-aspartate (NMDA). This neu roprotective activity of PAI-l is restricted to the necrotic cell death mediated by NMDA, because no effect has been observed against either kainate-mediated necrosis or apoptotic paradigms (Buisson et aI., 1998) . It has also been reported that PN-l protects cultured rat hippocam pal neurons from glucose deprivation-induced damage through attenuation of the increase in intracellular cal cium levels associated with such damage. This protection is abolished by an equimolar concentration of thrombin (Smith-Swintowsky et aI., 1995) . PN-I also can rescue spinal motoneurons during the period of programmed cell death that naturally occurs during ontogenesis (Houenou et aI., 1995) . In many biologic systems, the expression of the serine protease/serpin axis is modulated by various cytokines. In the CNS, this control by cytokines has not been ex tensively studied and remains speculative. Nevertheless, recent data have described a control of serine protease expression by neurotrophins. It has been demonstrated that brain-derived neurotrophic factor, neurotrophins 4 and 3, and nerve growth factor increase the secretion of plasminogen and u-PA from microglia (Nakajima et aI., 1998) . Thus, neurotrophic factors may contribute to changes associated with synaptic plasticity by means of a modulation of t-PA expression (Fiumelli et aI., 1999) . Other cytokines have been shown to decrease t-PA ac tivity by up-regulating the expression of PAl-I. Interleu kin-I � induces a dose-dependent decrease in t-PA activ ity in cultured astrocytes through an overexpression of PAI-l (Rogister et aI., J990) . Basic fibroblast growth factor (b-FGF) also can induce an accumulation of PAI-l mRNA in astrocytes in vitro (Rogister et aI., 1988) . In a comparable study, both transforming growth factor-� 1 (TGF-� 1) and b-FGF stimulated P AI-l mRN A expres sion in astrocytes with a maximal 5-fold increase for b-FGF and a 30-fold increase for TGF-� 1 (Treichel et Proposed mechanism for the involvement of the tissue-type plasminogen activator (t-PA)/type 1 plasminogen activator inhibitor (PAI-1) axis in the central nervous system during acute stroke. Intravenous in jection of t-PA is used for the treat ment of focal cerebral infarction in humans (thrombolysis). In the cere bral parenchyma, t-PA could be re leased from stressed neurons (Gual andris et aI., 1996) and could poten tiate excitotoxin-mediated neuronal cell death (Tsirka et aI., 1995) . The expression of transforming growth factor-i3 1 (TGF-i31) is up-regulated after either permanent or transient cerebral ischemia in rodents (Vivien et aI., 1998) . Then, TGF-i31 induces an overexpression of PAI-1 in astro cytes, a mechanism leading to the neuroprotective activity of TGF-i3 against N-methyl-D-aspartate (NMDA)-mediated excitotoxicity (Buisson et aI., 1998) . Concerning these results, we can postulate that the neuroprotective activity of TGF-131 and PAI-1 could be related to their inhibitory effects on t-PA. All these results suggest that both endogenous t-PA and recombinant t-PA used for thrombolysis may interfere in the control of the neuronal outcome after stroke in humans.
aI., 1998). The expression of the thrombin inhibitor PN-l is also under the control of cytokines. For example, in jury-related cytokines such as interleukin-I , tumor ne crosis factor-a, and TGF-13 can stimulate the secretion of PN -1 by the neuronal and glial cells from a neuroblas toma cell line (Vaughan et aI., 1993) .
Among the cytokines involved in the control of the expression of both serine proteases and serpins, TGF-13 1 has been described as an important regulator of PAI-I expression in the vascular system. In the eNS, TGF-13 1 is overexpressed after various types of injury (Kriegl stein and Kreiglstein, 1998) . In vitro, TGF-13 1 exerts a neuroprotective activity against NMDA-induced neuro nal death (see Fig. 2B ) but only in mixed cultures of neurons and astrocytes, which would suggest that astro cytes mediate this effect. These data have been con firmed by the blockade of TGF-l3's neuroprotective ac tivity after a selective transfection of astrocytes with a dominant negative receptor for TGF-I3. Moreover, the neuroprotection induced by TGF-13 1 is prevented by the addition of an antibody raised against PAI-l and is mim icked by the coapplication of the recombinant form of PAI-1 (see Fig. 2B ). These data suggest that the neuro protective activity of TGF-13 1 occurs by means of up regulation of PAI-l in astrocytes (Buisson et aI., 1998) . This study has given evidence for a tight link between TGF-13 1 and the serpins in the eNS. TGF-13 1 belongs to a large family of peptides including activin and bone morphogenetic proteins, which are known to be ex pressed in the eNS (Dewulf et aI., 1995; Ebendal et aI., 1998) . Recently, two other members of the same family, termed the glial cell line-derived neurotrophic factor (Lin et aI., 1993) and neurturin (Kotzbauer et aI., 1996) , have been identified in brain tissues. Although TGF-13 1 and activin can enhance the expression of PAI-1 in astrocytes (Docagne et aI., 1999) , bone morphogenetic proteins, glial cell line-derived neurotrophic factor, and neurturin are devoid of this activity.
These results provide novel insights into the regulation of the serpinlt-PA axis and the mechanisms by which an injury-related cytokine, such as TGF-I3, may be neuro protective in a situation of induced excitotoxicity.
SERINE PROTEASE INHIBITORS: A THERAPEUTIC TARGET FOR LIMITING ISCHEMIC BRAIN DAMAGE?
The idea that serine proteases-or more precisely the balance between serine proteases and serpins-may be involved in regulating neuronal fate during eNS devel opment is now widely accepted. In the adult brain, serine proteases have been extensively studied for their role in synaptic plasticity. In pathologic conditions, there is in creasing evidence to suggest an involvement of serine proteases and their inhibitors in neurodegenerative dis eases.
Data obtained using transgenic mice indicate that ser ine proteases participate in the neuronal death observed in acute brain injury. Most studies have focused on the involvement of t-PA in acute brain injury because of its clinical relevance. The experimental data obtained from studies with t-PA-deficient mice have led to the same conclusion: t-PA participates in excitotoxic neuronal death (Chen and Strickland, 1997; Tsirka et aI., 1995 Tsirka et aI., , 1997a Tsirka et aI., , 1997b and ischemia-induced neuronal death (Nagai et aI., 1999; Wang et aI., 1998) . This conclusion is reinforced by the results obtained in PAl-I-deficient mice (Nagai et aI., 1999) . The involvement of t-PA in the excitotoxic pathway is still not well understood. Does it involve the activation of plasminogen into plasmin, or is it a direct action of t-PA? The answer remains unclear. Studies based on in vitro models of excitotoxicity may help to elucidate the cellular mechanisms through which t-PA participates in excitotoxic cell death. t-PA is not the only serine protease believed to be involved in the con trol of neuronal death. Thrombin seems to be implicated in the control of the viability of both astrocytes and neu rons after different types of stimuli in vitro. Overall, these data suggest that the blockade of the activity of serine proteases might be beneficial in various types of CNS injury.
These experimental results have raised the question of the possible side effects of t-PA in stroke treatment in humans. Clinical studies have revealed that t -P A treat ment is clearly beneficial in the treatment of acute stroke. However, because the ischemic lesion is thought to prog ress largely by an excitotoxic pathway, the data that dem onstrate that serine proteases may potentiate excitotoxin induced neurodegeneration raise the question of potential risks in the use of t -P A for the treatment of acute stroke. The disruption of the blood-brain barrier that occurs in cerebral ischemia may facilitate the access of systemi cally administered t-PA to neuronal tissues, thus poten tiating neuronal death. As discussed above, the results obtained from rodents treated with intravenous t-PA and subjected to focal cerebral ischemia remain controver sial. These discrepancies could be the result of differ ences in the t-PA regimen, such as the dose of t-PA or the type of paradigm used to induce neuronal death. Because of its clinical relevance, researchers should make a con certed effort to clarify this issue. The idea that thrombo lytic agents may be used in combination with potent neuroprotective agents merits further attention. Because serine protease inhibitors specific for t-PA are neuropro tective, it is possible to suggest novel ways to counteract the neuronal death observed in acute stroke. The inhibi tion of the proteolytic activity of serine proteases on the cerebral parenchyma or the potentiation of serpin expres sion in brain cells could be a potential therapeutic inter vention for disorders in which excitotoxicity is thought to play a critical role. These observations raise the pos sibility of distinguishing potentially neurotoxic effects of t -P A from its beneficial effect on reperfusion; the expec tation would be that a combination of serine proteases and their inhibitors may usefully complement each other .1 Cereh Blood Flow Metab. Vol. 20. No. 5, 2000 in the treatment of cerebral ischemia in the clinical set ting (Fig. 3) . Because PAI-l would also block the ben eficial effect of t -P A on the original clot, one could en visage initial treatment with t-PA followed by a second application of serpin. According to the data presented in this review, the roles and the mechanisms of action of serine proteases and their inhibitors in the CNS deserve greater consideration by the scientific and medical com munities.
